People · Operator
Named in public records as an officer, director or promoter · active 2018–2018 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amphivena Therapeutics, Inc. | — | Biotechnology | Series B | $65.2M | $1.5B | 2018 |
Peter Van Vasselaer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter Van Vasselaer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Luke Evnin | 1 | 12 |
| ERIC MOESSINGER | 1 | 6 |
| Mark McDade | 1 | 5 |
| Frank Muhlenbeck | 1 | 4 |
| Phil Gutry | 1 | 4 |
| Jeanmarie Guenot | 1 | 2 |
| Christian Richard | 1 | 2 |
| Adi Hoess | 1 | 1 |
| Vinay Bhaskar | 1 | 1 |
| Florian Fischer | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.